GlobeNewswire Inc.··Not SpecifiedMonopar Strengthens Balance Sheet With $92M Raise, Eyes 2026 Drug Submission
Monopar reports $13.7M net loss, $140.4M cash reserves funding operations through 2027. Company plans mid-2026 NDA submission for Wilson disease treatment ALXN1840.
MNPRfinancial resultsFDA approval